Masimo (MASI) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
4 May, 2026Opening remarks and agenda
Meeting called to order by the CEO, with recording available for replay for one week.
Inspector of Election appointed and sworn in; voting instructions provided for virtual attendees.
CEO expressed gratitude to shareholders and employees, highlighting achievements and strategic direction.
Specific resolutions to be voted on
Proposal to adopt the merger agreement with Danaher Corporation and Mobius Merger Sub, Inc.
Proposal for non-binding advisory approval of compensation for named executive officers related to the merger.
Discussions on mergers, acquisitions, or other significant changes
Merger agreement involves Masimo becoming a wholly owned subsidiary of Danaher, while remaining an independent operating company within Danaher's diagnostics sector.
CEO emphasized benefits of the merger, including expanded opportunities for employees and stakeholders.
Latest events from Masimo
- Revenue up 8.5% to $403.6M; merger with Danaher approved; net income $57.1M.MASI
Q1 20266 May 2026 - Shareholders to vote on $180 per share Danaher merger, with board support and litigation addressed.MASI
Proxy filing23 Apr 2026 - Shareholders to vote on $180/share all-cash merger with Danaher and related executive compensation.MASI
Proxy filing1 Apr 2026 - Stockholders to vote on $180/share Danaher acquisition, with board unanimous support and premium offered.MASI
Proxy Filing18 Mar 2026 - $1B credit facility signed in Dec 2025 with leverage and coverage covenants, maturing 2030.MASI
Q4 202527 Feb 2026 - Masimo to be acquired by Danaher for $180 per share, pending shareholder approval.MASI
Proxy Filing17 Feb 2026 - Board approves $180/share Danaher acquisition; shareholder vote and regulatory review pending.MASI
Proxy Filing17 Feb 2026 - Shareholders will vote on a $180/share all-cash merger, with closing expected in late 2026.MASI
Proxy Filing17 Feb 2026 - Q2 revenue up 9% to $496.3M, driven by healthcare growth; non-GAAP EPS $0.86, guidance raised.MASI
Q2 20242 Feb 2026